NCT05085002
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with inflammatory breast cancer; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients who have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy) or any CDK4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib); Patients who have received prior treatment with fulvestrant or systemic estrogens
https://ClinicalTrials.gov/show/NCT05085002